同步放化疗联合重组人血管内皮抑制素与单纯同步放化疗治疗局部晚期鼻咽癌的疗效比较:一项回顾性研究
该回顾性研究纳入2016年11月至2019年3月初治的局部晚期鼻咽癌患者88例,试验组接受同步放化疗联合重组人血管内皮抑制素(CCRT+E)43例,对照组接受单纯同步放化疗(CCRT)45例。中位随访54.0个月,CCRT+E组3年无进展生存率和无远处转移生存率均优于CCRT组,颈部淋巴结消退完全缓解率更高,但3/4级白细胞减少发生率更高。
要点
- CCRT+E组3年无进展生存率81.4% vs CCRT组63.6%(HR 0.418,95%CI 0.181-0.963,P=0.034)。
- CCRT+E组3年无远处转移生存率88.3% vs CCRT组77.3%(HR 0.370,95%CI 0.132-1.039,P=0.049)。
- CCRT+E组3/4级白细胞减少发生率32.6% vs CCRT组13.3%(P=0.031)。
核心结论
- CCRT+E显著延长局部晚期鼻咽癌患者的3年无进展生存期和无远处转移生存期,且淋巴结消退情况更好。
研究设计与样本
- 回顾性分析2016年11月至2019年3月初治的局部晚期鼻咽癌患者,试验组接受同步放化疗联合重组人血管内皮抑制素(CCRT+E),对照组接受单纯同步放化疗(CCRT)。
主要发现
- 共纳入88例患者,CCRT+E组43例,CCRT组45例,中位随访时间54.0个月(范围8.0-64.0个月)。
- CCRT+E组与CCRT组3年无进展生存率分别为81.4%和63.6%(HR 0.418,95%CI 0.181-0.963,P=0.034)。
- CCRT+E组与CCRT组3年无远处转移生存率分别为88.3%和77.3%(HR 0.370,95%CI 0.132-1.039,P=0.049)。
- CCRT+E组与CCRT组3年总生存率分别为88.2%和81.9%(HR 0.437,95%CI 0.151-1.260,P=0.114)。
- CCRT+E组与CCRT组3年无局部区域失败生存率分别为87.8%和86.9%(HR 0.795,95%CI 0.242-2.616,P=0.705)。
关键数值与推荐
- 放疗后3个月颈部淋巴结消退完全缓解率:CCRT+E组97.7% vs CCRT组82.2%(P=0.041)。
- 淋巴结坏死完全缓解率:CCRT+E组100% vs CCRT组80.0%(P=0.001)。
- 结外延伸完全缓解率:CCRT+E组100% vs CCRT组85.2%(P=0.041)。
- 3/4级白细胞减少发生率:CCRT+E组32.6% vs CCRT组13.3%(P=0.031),晚期毒性结果相似。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To retrospectively analyze the efficacy and safety of concurrent chemoradiotherapy (CCRT) plus recombinant human endostatin (Endostar, CCRT + E) versus CCRT alone in locally advanced nasopharyngeal carcinoma (LANPC). METHODS: A retrospective analysis of patients initially treated for LANPC from November 2016 to March 2019 was performed: trial group received CCRT + E and control group received CCRT. Prognoses and adverse effects were evaluated. RESULTS: Eighty-eight patients were included: 43 received CCRT + E and 45 received CCRT. The median follow-up time was 54.0 (range: 8.0-64.0) months. The survival data of the CCRT + E and CCRT groups were as follows: 3-year progression-free survival (PFS) rates, 81.4% and 63.6% (hazard ratio [HR] 0.418, 95%CI 0.181-0.963, P = 0.034); 3-year distant metastasis-free survival (DMFS) rates, 88.3% and 77.3% (HR 0.370, 95%CI 0.132-1.039, P = 0.049); 3-year overall survival rates, 88.2% and 81.9% (HR 0.437, 95%CI 0.151-1.260, P = 0.114); and 3-year locoregional failure-free survival rates, 87.8% and 86.9% (HR 0.795, 95%CI 0.242-2.616, P = 0.705). Three months after radiotherapy, the complete response (CR) rates of cervical lymph node regression were 97.7% and 82.2% for the CCRT + E and CCRT groups (P = 0.041). The corresponding CR rates were 100% and 80.0% for lymph node necrosis (P = 0.001) and 100% and 85.2% for extranodal extension (P = 0.041). The CCRT + E group had higher incidence of grade 3/4 leukopenia (32.6% vs. 13.3%, P = 0.031), with similar results for late toxicity. CONCLUSIONS: CCRT + E significantly prolonged 3-year PFS and DMFS in LANPC, and patients had better lymph node regression.
引用
- Yin Y, Zhou Z, Li Z, et al. Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study. Radiat Oncol. 2022. PMID: 35906636. doi:10.1186/s13014-022-02104-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。